The Gene Expression Landscape of Prostate Cancer BM Reveals Close Interaction with the Bone Microenvironment.
BM
prostate cancer
transcriptome
tumor microenvironment
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
27 Oct 2022
27 Oct 2022
Historique:
received:
12
09
2022
revised:
12
10
2022
accepted:
23
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
15
11
2022
Statut:
epublish
Résumé
Bone metastatic (BM) prostate cancer (PCa) belongs to the most lethal form of PCa, and therapeutic options are limited. Molecular profiling of metastases contributes to the understanding of mechanisms defining the bone metastatic niche. Our aim was to explore the transcriptional profile of PCa BM and to identify genes that drive progression. Paraffin-embedded tissues of 28 primary PCa and 30 BM were submitted to RNA extraction and analyzed by RNA sequencing using the Nanostring nCounter gene expression platform. A total of 770 cancer-related genes were measured using the Nanostring™ PanCancer progression panel. Gene Ontology (GO), KEGG, Reactome, STRING, Metascape, PANTHER, and Pubmed were used for data integration and gene annotation. We identified 116 differentially expressed genes (DEG) in BM compared to primaries. The most significant DEGs include
Identifiants
pubmed: 36361816
pii: ijms232113029
doi: 10.3390/ijms232113029
pmc: PMC9656691
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : SPP2084
Références
J Transl Med. 2019 Oct 26;17(1):352
pubmed: 31655604
Sci Signal. 2009 May 26;2(72):re3
pubmed: 19471024
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436
pubmed: 31061129
FEBS Open Bio. 2020 Apr;10(4):674-688
pubmed: 32027093
EBioMedicine. 2019 Jul;45:108-123
pubmed: 31262715
Pathol Res Pract. 2020 Oct;216(10):153109
pubmed: 32853947
Biomed Res Int. 2018 Jul 4;2018:7801202
pubmed: 30069479
Mol Oncol. 2019 Aug;13(8):1763-1777
pubmed: 31162796
Oncogene. 2018 Apr;37(17):2285-2301
pubmed: 29398710
Cancer Res. 2001 Dec 15;61(24):8896-902
pubmed: 11751414
World J Surg Oncol. 2016 Nov 29;14(1):297
pubmed: 27894325
Immunol Invest. 2011;40(5):447-64
pubmed: 21391788
BMC Cancer. 2007 Apr 12;7:64
pubmed: 17430594
Prostate Cancer Prostatic Dis. 2021 Jun;24(2):310-322
pubmed: 33452452
BMC Cancer. 2021 Aug 12;21(1):914
pubmed: 34380460
J Pathol Clin Res. 2019 Oct;5(4):272-286
pubmed: 31464093
Trends Cancer. 2021 Feb;7(2):112-121
pubmed: 33274720
Sci Transl Med. 2019 Feb 6;11(478):
pubmed: 30728288
Cancers (Basel). 2021 Mar 31;13(7):
pubmed: 33807333
Cancer Res. 2014 Aug 15;74(16):4230-8
pubmed: 24950910
Nature. 2017 Aug 17;548(7667):297-303
pubmed: 28783718
Nature. 2002 Jan 31;415(6871):530-6
pubmed: 11823860
J Urol. 2016 Jun;195(6):1892-902
pubmed: 26631499
Lung. 2015 Aug;193(4):583-92
pubmed: 25851596
Ann Transl Med. 2020 Aug;8(16):993
pubmed: 32953793
Hum Pathol. 2000 May;31(5):578-83
pubmed: 10836297
Cancer Res. 2006 Jan 15;66(2):883-8
pubmed: 16424021
Cold Spring Harb Perspect Biol. 2011 Dec 01;3(12):
pubmed: 21917992
PLoS One. 2021 Sep 16;16(9):e0257416
pubmed: 34529723
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
BMC Cancer. 2014 Aug 23;14:609
pubmed: 25151367
Cancer. 2020 Mar 1;126(5):986-993
pubmed: 31769876
Cancer Res. 2008 Aug 1;68(15):6251-9
pubmed: 18676849
Tumour Biol. 2016 Jan;37(1):253-62
pubmed: 26198048
Cancer. 2018 Mar 1;124(5):1008-1015
pubmed: 29266381
Oncotarget. 2017 Sep 8;8(54):92055-92063
pubmed: 29190897
Nat Rev Clin Oncol. 2021 Aug;18(8):488-505
pubmed: 33875860